Expression of CD44 by rhabdomyosarcoma: a new prognostic marker?
The expression pattern of CD44 standard and variant isoforms are prognostically significant in a number of malignancies. The aim of this study was to evaluate the role of the standard isoform of CD44 in predicting the clinical behaviour of rhabdomyosarcoma. Immunohistochemical analysis of CD44 was undertaken using a panel of antibodies recognizing the three core domains of the CD44 molecule. Labelling was repeated in triplicate and reported blind with respect to histological type and outcome. Tumours were characterized as positive in more than 60% of tumour cells labelled and negative if less than 40% of tumour cells labelled. Tumours with 40-60% of tumour cells labelling were considered indeterminate. Eleven of 20 favourable histology tumours were positive for CD44 compared with one of seven unfavourable tumours (P = 0.07). Eleven of 12 patients with CD44-positive tumours are alive in first remission compared with five of 15 CD44-negative tumours (P = 0.001). Expression of CD44 correlates directly with prognosis; however, larger studies are required so that multivariate analysis can be undertaken.
Humphrey
G
G
Department of Paediatric Oncology, St James's University Hospital, Leeds, UK.
Hazel
D L
DL
MacLennan
K
K
Lewis
I
I
D000293:Adolescent; D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D018960:Hyaluronan Receptors / Q000096:biosynthesis*; D007150:Immunohistochemistry; D007223:Infant; D008297:Male; D011379:Prognosis; D011446:Prospective Studies; D012208:Rhabdomyosarcoma / Q000378:metabolism* / Q000473:pathology
D014408:Biomarkers, Tumor; D018960:Hyaluronan Receptors